Secretory kinase FAM20C triggers adipocyte dysfunction, inciting insulin resistance and inflammation in obesity
Obesity is a major driver of type 2 diabetes (T2D) and related metabolic disorders, characterized by chronic inflammation and adipocyte dysfunction. However, the molecular triggers initiating these processes remain poorly understood. We identified FAM20C, a serine/threonine kinase, as an early obesity-induced mediator of adipocyte dysfunction. Fam20c expression was substantially upregulated in adipocytes in response to obesity, correlating with a proinflammatory transcriptional signature. Forced expression of Fam20c in adipocytes promoted robust upregulation of proinflammatory cytokines and induced insulin resistance that is dependent on its kinase activity. Conversely, deletion of adipocyte Fam20c after established obesity and hyperglycemia improved glucose tolerance, augmented insulin sensitivity, and reduced visceral adiposity, without altering body weight. Phosphoproteomic studies revealed that FAM20C regulates phosphorylation of intracellular and secreted proteins, modulating pathways critical to inflammation, metabolism, and ECM remodeling. We identified FAM20C-dependent substrates, such as CNPY4, whose phosphorylation contributes to proinflammatory adipocyte signaling. Of translational relevance, we showed that in humans, visceral adipose FAM20C expression positively correlates with insulin resistance. Our findings establish FAM20C as an early regulator of obesity-induced adipocyte dysfunction and systemic metabolic impairment. Our studies provide proof of concept that inhibition of FAM20C may serve as a potential therapy for T2D by restoring adipocyte health.
Authors
- Renan Pereira de Lima (ORCID: https://orcid.org/0000-0001-9653-7037)
- Adhideb Ghosh (ORCID: https://orcid.org/0000-0002-5160-4571)
- Ankit Gilani (ORCID: https://orcid.org/0000-0002-5100-0110)
- Anne Hoffmann (ORCID: https://orcid.org/0000-0003-3258-3397)
- Christian Wolfrum (ORCID: https://orcid.org/0000-0002-3862-6805)
- Edwin A. Homan (ORCID: https://orcid.org/0000-0002-2923-9635)
- Elizabeth E. Ha (ORCID: https://orcid.org/0000-0003-2948-315X)
- Lunkun Ma
- Bhavneet Bhinder (ORCID: https://orcid.org/0000-0001-6685-8761)
- Falko Noé (ORCID: https://orcid.org/0009-0002-3360-5455)
- James C. Lo (ORCID: https://orcid.org/0000-0003-0244-1670)
- Olivier Elemento (ORCID: https://orcid.org/0000-0002-8061-9617)
- Benjamin D. Stein (ORCID: https://orcid.org/0000-0003-1187-1779)
- Alfonso Rubio‐Navarro (ORCID: https://orcid.org/0000-0001-5677-3123)
- Matthias Blüher (ORCID: https://orcid.org/0000-0003-0208-2065)
- Tint Tha Ra Wun
- Gabriel Jose Ayala Carrascal
Institutions
- Cornell University (US)
- Lander Institute (IL)
- ETH Zurich (CH)
- University Hospital Leipzig (DE)
- Institut des Maladies Métaboliques et Cardiovasculaires (FR)
- Weill Cornell Medicine (US)
Publication Details
- Journal
- Journal of Clinical Investigation
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1172/jci191075
- Citations
- 1
- Primary Topic
- Adipokines, Inflammation, and Metabolic Diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- American Diabetes Association
- American Heart Association
- Amgen
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- Fresenius Medical Care North America
- Deutsche Forschungsgemeinschaft
- Novo Nordisk
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases
- National Institute of Diabetes and Digestive and Kidney Diseases